IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
IGC Pharma has been selected as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). The company is developing AI-driven tools for early Alzheimer's disease detection using acoustic biomarkers from voice recordings.
The company's approach utilizes multilingual AI models to enhance predictive accuracy across diverse populations, including English, Spanish, and Chinese speakers. This initiative aligns with IGC Pharma's broader mission to integrate AI with pharmaceutical innovation in Alzheimer's care.
The next stage of the competition will focus on demonstrating the AI model's ability to identify cognitive changes across diverse demographic groups. If selected as one of three winners, IGC will work on improving model interpretability while maintaining transparency. With the global Alzheimer's diagnostic market projected to exceed $10 billion by 2028 and over 7 million Americans living with Alzheimer's, early detection remains a critical unmet need.
IGC Pharma è stata selezionata come una delle 15 finaliste nel PREPARE Challenge - Fase 2: Model Arena (Acoustic Track), organizzato dal National Institute on Aging (NIA). L'azienda sta sviluppando strumenti basati su IA per la rilevazione precoce dell'Alzheimer utilizzando biomarcatori acustici provenienti da registrazioni vocali.
L'approccio della compagnia utilizza modelli di IA multilingue per aumentare l'accuratezza predittiva attraverso diverse popolazioni, incluse quelle di lingua inglese, spagnola e cinese. Questa iniziativa si allinea con la missione più ampia di IGC Pharma di integrare l'IA con l'innovazione farmaceutica nella cura dell'Alzheimer.
La prossima fase della competizione si concentrerà sulla dimostrazione della capacità del modello di IA di identificare cambiamenti cognitivi in diversi gruppi demografici. Se selezionata come uno dei tre vincitori, IGC lavorerà per migliorare l'interpretabilità del modello, mantenendo al contempo la trasparenza. Con il mercato globale della diagnostica dell'Alzheimer che si prevede supererà 10 miliardi di dollari entro il 2028 e oltre 7 milioni di americani che convivono con l'Alzheimer, la rilevazione precoce rimane un bisogno critico non soddisfatto.
IGC Pharma ha sido seleccionada como una de las 15 finalistas en el PREPARE Challenge - Fase 2: Model Arena (Acoustic Track), organizado por el National Institute on Aging (NIA). La empresa está desarrollando herramientas impulsadas por IA para la detección temprana de la enfermedad de Alzheimer utilizando biomarcadores acústicos de grabaciones de voz.
El enfoque de la compañía utiliza modelos de IA multilingües para mejorar la precisión predictiva en diversas poblaciones, incluidos hablantes de inglés, español y chino. Esta iniciativa se alinea con la misión más amplia de IGC Pharma de integrar la IA con la innovación farmacéutica en el cuidado del Alzheimer.
La próxima etapa de la competencia se centrará en demostrar la capacidad del modelo de IA para identificar cambios cognitivos en diferentes grupos demográficos. Si es seleccionada como una de las tres ganadoras, IGC trabajará en mejorar la interpretabilidad del modelo manteniendo la transparencia. Con el mercado global de diagnóstico de Alzheimer proyectado para superar los 10 mil millones de dólares para 2028 y más de 7 millones de estadounidenses viviendo con Alzheimer, la detección temprana sigue siendo una necesidad crítica insatisfecha.
IGC Pharma는 노인국(NIA) 주관의 PREPARE Challenge - Phase 2: Model Arena (Acoustic Track)에서 상위 15개 최종 후보 중 하나로 선정되었습니다. 이 회사는 음성 녹음에서의 음향 바이오마커를 사용하여 알츠하이머 병을 조기에 탐지하기 위한 AI 기반 도구를 개발하고 있습니다.
회사의 접근 방식은 영어, 스페인어 및 중국어를 포함한 다양한 인구에 걸쳐 예측 정확성을 향상시키기 위해 다국어 AI 모델을 활용합니다. 이 이니셔티브는 알츠하이머 치료에서 제약 혁신과 AI를 통합하려는 IGC Pharma의 더 넓은 목표와 일치합니다.
경쟁의 다음 단계는 다양한 인구 통계 그룹에서 인지 변화를 식별하는 AI 모델의 능력을 입증하는 데 중점을 둡니다. 세 명의 수상자 중 하나로 선정될 경우, IGC는 투명성을 유지하면서 모델 해석 가능성을 향상시키기 위해 작업할 것입니다. 글로벌 알츠하이머 진단 시장이 2028년까지 100억 달러를 초과할 것으로 예상되고 700만 명 이상의 미국인이 알츠하이머와 함께 살고 있어 조기 발견은 여전히 중요한 미충족 수요로 남아 있습니다.
IGC Pharma a été sélectionnée comme l'une des 15 finalistes du PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organisé par le National Institute on Aging (NIA). L'entreprise développe des outils basés sur l'IA pour la détection précoce de la maladie d'Alzheimer en utilisant des biomarqueurs acoustiques issus d'enregistrements vocaux.
La démarche de l'entreprise utilise des modèles d'IA multilingues pour améliorer la précision prédictive à travers diverses populations, y compris des locuteurs d'anglais, d'espagnol et de chinois. Cette initiative s'inscrit dans la mission plus large d'IGC Pharma d'intégrer l'IA avec l'innovation pharmaceutique dans le soin de l'Alzheimer.
La prochaine étape de la compétition sera axée sur la démonstration de la capacité du modèle d'IA à identifier les changements cognitifs au sein de différents groupes démographiques. Si IGC est sélectionnée comme l'une des trois gagnantes, elle s'attachera à améliorer l'interprétabilité du modèle tout en maintenant la transparence. Avec un marché mondial du diagnostic de l'Alzheimer qui devrait dépasser 10 milliards de dollars d'ici 2028 et plus de 7 millions d'Américains vivant avec l'Alzheimer, la détection précoce reste un besoin critique non satisfait.
IGC Pharma wurde als eines der 15 besten Finalisten im PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organisiert vom National Institute on Aging (NIA), ausgewählt. Das Unternehmen entwickelt KI-gestützte Werkzeuge zur frühen Erkennung der Alzheimer-Krankheit, die akustische Biomarker aus Sprachaufnahmen verwenden.
Der Ansatz des Unternehmens nutzt mehrsprachige KI-Modelle zur Verbesserung der Vorhersagegenauigkeit in verschiedenen Bevölkerungsgruppen, einschließlich Englisch-, Spanisch- und Chinesischsprechenden. Diese Initiative stimmt mit der breiteren Mission von IGC Pharma überein, KI mit pharmazeutischer Innovation in der Alzheimer-Versorgung zu integrieren.
Die nächste Phase des Wettbewerbs wird sich darauf konzentrieren, die Fähigkeit des KI-Modells zu demonstrieren, kognitive Veränderungen in verschiedenen demografischen Gruppen zu identifizieren. Wenn IGC als einer der drei Gewinner ausgewählt wird, wird das Unternehmen daran arbeiten, die Interpretierbarkeit des Modells zu verbessern und gleichzeitig die Transparenz zu wahren. Da der globale Markt für Alzheimer-Diagnostik voraussichtlich bis 2028 10 Milliarden Dollar überschreiten wird und mehr als 7 Millionen Amerikaner mit Alzheimer leben, bleibt die frühzeitige Erkennung ein kritischer unerfüllter Bedarf.
- None.
- None.
POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge - Phase 2: Model Arena (Acoustic Track), organized by the National Institute on Aging (NIA). This recognition highlights IGC's innovative application of artificial intelligence (AI) and machine learning to advance early detection of Alzheimer's disease (AD) and improve patient outcomes.
The PREPARE Challenge, sponsored by the NIA, encourages novel approaches for early AD detection using AI-driven tools that improve accuracy, affordability, and accessibility for patients. As a finalist, IGC developed prediction methods for Alzheimer's disease and related dementias (AD/ADRD) using AI to analyze acoustic biomarkers derived from voice recordings.
"Being named a top 15 finalist reflects IGC Pharma's leadership in leveraging cutting-edge AI technology to address critical gaps in Alzheimer's care," said Ram Mukunda, CEO of IGC Pharma. "Our approach applies multilingual AI models that enhance predictive accuracy, but also ensure cultural relevance across diverse populations including English, Spanish, and Chinese speakers. Our work to address disparities in early detection of Alzheimer's can ultimately improve outcomes for patients worldwide.
"This recognition by the NIA aligns with our broader mission to integrate AI with pharmaceutical innovation in Alzheimer's care. Beyond diagnostics, our AI-driven solutions are designed to optimize treatment efficacy, ultimately creating long-term value for patients, healthcare systems, and shareholders alike."
In the next stage of the competition, IGC Pharma will showcase the ability of its AI model to identify cognitive changes across diverse demographic groups. If selected as one of the three winners, the next phase of the challenge will consist of improving interpretability which can provide actionable insights for healthcare providers while maintaining a high level of transparency.
With over 7 million Americans living with Alzheimer's and the global Alzheimer's diagnostic market projected to exceed
For more information about the PREPARE Challenge, visit the following link.
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ("CALMA") associated with Alzheimer's (clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is IGC Pharma's role in the NIA PREPARE Challenge for Alzheimer's detection?
How does IGC Pharma's AI technology address diverse populations in Alzheimer's detection?
What is the market potential for IGC Pharma's Alzheimer's diagnostic technology?
What are the next steps for IGC in the PREPARE Challenge competition?
How does IGC Pharma's AI technology contribute to Alzheimer's care?
